Norwegian Olympic Sports Centre, Norwegian Olympic and Paralympic Committee and Confederation of Sports, Oslo, Norway.
Department of Physical Performance, Norwegian School of Sport Sciences, Oslo, Norway.
Scand J Med Sci Sports. 2021 Sep;31(9):1764-1773. doi: 10.1111/sms.13982. Epub 2021 May 11.
The present study explored the impact of pre-altitude serum (s)-ferritin and iron supplementation on changes in hemoglobin mass (ΔHbmass) following altitude training. Measures of Hbmass and s-ferritin from 107 altitude sojourns (9-28 days at 1800-2500 m) with world-class endurance athletes (males n = 41, females n = 25) were analyzed together with iron supplementation and self-reported illness. Altitude sojourns with a hypoxic dose [median (range)] of 1169 (912) km·h increased Hbmass (mean ± SD) 36 ± 38 g (3.7 ± 3.7%, p < 0.001) and decreased s-ferritin -11 (190) µg·L (p = 0.001). Iron supplements [27 (191) mg·day ] were used at 45 sojourns (42%), while only 11 sojourns (10%) were commenced with s-ferritin <35 µg/L. Hbmass increased by 4.6 ± 3.7%, 3.4 ± 3.3%, 4.2 ± 4.3%, and 2.9 ± 3.4% with pre-altitude s-ferritin ≤35 µg·L , 36-50 µg·L , 51-100 µg·L , and >100 µg·L , respectively, with no group difference (p = 0.400). Hbmass increased by 4.1 ± 3.9%, 3.0 ± 3.0% and 3.7 ± 4.7% without, ≤50 mg·day or >50 mg·day supplemental iron, respectively (p = 0.399). Linear mixed model analysis revealed no interaction between pre-altitude s-ferritin and iron supplementation on ΔHbmass (p = 0.906). However, each 100 km·h increase in hypoxic dose augmented ΔHbmass by an additional 0.4% (95% CI: 0.1-0.7%; p = 0.012), while each 1 g·kg higher pre-altitude Hbmass reduced ΔHbmass by -1% (-1.6 to -0.5; p < 0.001), and illness lowered ΔHbmass by -5.7% (-8.3 to -3.1%; p < 0.001). In conclusion, pre-altitude s-ferritin or iron supplementation were not related to the altitude-induced increase in Hbmass (3.7%) in world-class endurance athletes with clinically normal iron stores.
本研究探讨了高原前血清(s)-铁蛋白和铁补充对高原训练后血红蛋白质量(ΔHbmass)变化的影响。分析了来自 107 次高原停留(9-28 天,海拔 1800-2500 米)的 107 名世界级耐力运动员(男性 n=41,女性 n=25)的 Hbmass 和 s-铁蛋白测量值,以及铁补充和自我报告的疾病。高原停留期间,低氧剂量[中位数(范围)]为 1169(912)km·h,血红蛋白质量增加 36±38 g(3.7±3.7%,p<0.001),s-铁蛋白降低-11(190)µg·L(p=0.001)。45 次停留(42%)使用了铁补充剂[27(191)mg·天],而只有 11 次停留(10%)是在 s-铁蛋白<35µg/L时开始的。高原前 s-铁蛋白≤35µg·L、36-50µg·L、51-100µg·L 和>100µg·L 时,Hbmass 分别增加了 4.6±3.7%、3.4±3.3%、4.2±4.3%和 2.9±3.4%,各组间无差异(p=0.400)。无铁补充剂、≤50mg·天或>50mg·天补充铁时,Hbmass 分别增加了 4.1±3.9%、3.0±3.0%和 3.7±4.7%(p=0.399)。线性混合模型分析显示,高原前 s-铁蛋白和铁补充剂对ΔHbmass 无交互作用(p=0.906)。然而,低氧剂量每增加 100km·h,ΔHbmass 就会额外增加 0.4%(95%CI:0.1-0.7%;p=0.012),而高原前 Hbmass 每增加 1g·kg,ΔHbmass 就会减少 1%(-1.6 至-0.5;p<0.001),疾病则会使ΔHbmass 减少 5.7%(-8.3 至-3.1%;p<0.001)。总之,在临床铁储存正常的世界级耐力运动员中,高原前 s-铁蛋白或铁补充剂与高原诱导的血红蛋白质量增加(3.7%)无关。